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Nkx2.5+ Cardiomyoblasts 
Contribute to Cardiomyogenesis in 
the Neonatal Heart
Vahid Serpooshan1, Yuan-Hung Liu2,3,4, Jan W. Buikema1,5, Francisco X. Galdos  1, Orlando 
Chirikian1,6, Sharon Paige1,7, Sneha Venkatraman1,6, Anusha Kumar1, David R. Rawnsley2, 
Xiaojing Huang2, Daniël A. Pijnappels2,8 & Sean M. Wu1,9,10
During normal lifespan, the mammalian heart undergoes limited renewal of cardiomyocytes. While the 
exact mechanism for this renewal remains unclear, two possibilities have been proposed: differentiated 
myocyte replication and progenitor/immature cell differentiation. This study aimed to characterize 
a population of cardiomyocyte precursors in the neonatal heart and to determine their requirement 
for cardiac development. By tracking the expression of an embryonic Nkx2.5 cardiac enhancer, we 
identified cardiomyoblasts capable of differentiation into striated cardiomyocytes in vitro. Genome-
wide expression profile of neonatal Nkx2.5+ cardiomyoblasts showed the absence of sarcomeric 
gene and the presence of cardiac transcription factors. To determine the lineage contribution of the 
Nkx2.5+ cardiomyoblasts, we generated a doxycycline suppressible Cre transgenic mouse under the 
regulation of the Nkx2.5 enhancer and showed that neonatal Nkx2.5+ cardiomyoblasts mature into 
cardiomyocytes in vivo. Ablation of neonatal cardiomyoblasts resulted in ventricular hypertrophy and 
dilation, supporting a functional requirement of the Nkx2.5+ cardiomyoblasts. This study provides 
direct lineage tracing evidence that a cardiomyoblast population contributes to cardiogenesis in the 
neonatal heart. The cell population identified here may serve as a promising therapeutic for pediatric 
cardiac regeneration.
The mammalian heart possesses a limited capacity for new cardiomyocyte (CM) formation after embryonic 
development1,2. The basal cardiomyocte renewal rate in human hearts has been estimated to about 1% annually in 
the neonate and 0.45% in adults1. However, these estimates vary greatly among studies, some describing annual 
cardiomyote turnover as high as 20%2. While the exact extent of CM renewal continues to be debated, two possi-
bilities have been proposed as possible mechanisms for their renewal: 1) new CMs are generated in the postnatal 
heart from the proliferation of pre-existing, differentiated CMs3–8; 2) a rare population of cardiac stem/progenitor 
cells contribute to normal cardiac development and tissue renewal during injury repair9–12.
The relative contribution by these distinct mechanisms to postnatal cardiomyogenesis has not been easily 
resolved due to the lack of an approach to identity the primitive cell population responsible for renewal. Until 
recently, there has been little data demonstrating that a postnatal cell population contributes directly to neocar-
diomyogenesis via cell labeling and lineage tracing in a prospective fashion9,13,14. While retrospective labeling 
studies confirm that cardiac stem/progenitor cells may contribute to endogenous cardiac renewal after injury9, 
this approach does not allow the identification of the precise cell population and the phenotypic characteristics 
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they possess. Hence, this lack of a defined precursor cell population in the neonatal heart that can mediate de novo 
cardiomyogenesis has limited current efforts in cardiac regenerative therapy15–18.
To identify a population of CM precursors that might be present in neonatal heart, we utilize a previously 
generated transgenic mouse model that expresses an eGFP reporter under the regulatory control of a 2.1 kb 
cardiac-specific enhancer of Nkx2.5, a key transcription factor in early cardiac development19. Distinct from 
the endogenous expression of Nkx2.5, which is initiated in cardiac progenitor cells and sustained throughout 
CM maturation, the eGFP expression in Nkx2.5 cardiac enhancer-eGFP transgenic mice (hereto referred as 
Nkx2.5 enh-eGFP) is restricted to cardiac progenitor cells and early immature CMs19,20. Consequently, Nkx2.5 
enh-eGFP+ cells represent cardiac progenitor cells in the early fetal heart and we postulate that it may also label 
a population of cardiomyogenic precursors in the postnatal heart.
Cardiac progenitor cells, such as the Islet-1 (Isl-1)-positive cell population, has been described in the neonatal 
heart21. However, the direct contribution of Isl-1+ cells to cardiomyogenesis in the postnatal heart in vivo has not 
been demonstrated22,23. Given the cardiomyoblast-restricted expression of Nkx2.5 enh-eGFP transgene in the 
fetal heart, we explored whether a rare number of these cells may be present in the neonatal heart and contribute 
to normal development of the myocardium. In this study we identified a neonatal Nkx2.5 enh-eGFP+ cardio-
myoblast population and demonstrated their phenotypic and functional contribution to making new CMs. We 
further showed, by prospective lineage tracing using a doxycycline suppressible Nkx2.5 enhancer-Cre transgenic 
mouse line, that Nkx2.5 enh-eGFP+ cardiomyoblasts reside in the subepicardium and contribute directly to car-
diomyogenesis in vivo. Furthermore, the ablation of neonatal Nkx2.5 enh-eGFP+ cardiomyoblasts led to early 
heart failure phenotypes, including ventricular dilation and hypertrophy, consistent with a requirement for these 
cells in normal neonatal heart development.
Results
Isolation and in vitro characterization of a putative cardiomyoblast population in the neonatal 
heart. To determine the growth rate of the neonatal heart and its relationship with the growth of the overall 
body weight, we measured the heart weight and body weight in neonatal mice from birth to 21 days of life. We 
found a rapid rise in heart weight during this time period. The ratio of heart weight to body weight appeared to be 
stable during this developmental time frame (Fig. 1A–C). This finding demonstrated that a rapid growth occurs 
in the developing heart after birth. We hypothesized that postnatal cardiomyoblasts may contribute to the prolif-
erating cells in the neonatal heart. Previously described Nkx2.5 enh-eGFP transgenic mice were used to isolate 
and characterize these cells19,20. The expression of eGFP in Nkx2.5 enh-eGFP mice labels cardiac precursor cells in 
the developing embryo and wanes when these cells mature into striated CMs20. Interestingly, by flow cytometric 
analysis of neonatal hearts from Nkx2.5 enh-eGFP mice, we found a resurgence of eGFP+ cell population during 
the first three weeks after birth (Fig. 1D,E).
qPCR analysis of sorted eGFP+ and eGFP- cells at postnatal day 6 demonstrated significant differences in the 
gene expression profiles of these cells (Fig. 1F). The proliferation capacity of the eGFP+ cells was quantified by 
determining the proportion of these cells in S or G2 phase of the cell cycle as measured by their incorporation of 
the DNA analog BrdU vs their DNA content (7-AAD) (Fig. 1G,H). We found that the proportion of eGFP+ cells 
in S phase declined from 8.4% at postnatal day 6 to 0.75% at day 22 while the proportion in G0/1 phase increased 
from 83% at day 6 to 89% at day 22. P6 eGFP+ were also isolated, cultured in vitro, and immunostained for 
proliferation markers including Ki67 and pH3 at days 1 and 5 in culture (Supplementary Figure S1). Confocal 
microscopy demonstrated a notable percentage of eGFP+ cells were Ki67+ (~30% at day 1 and 20% at day 5) and 
pH3+ (~18% at day 1 and 12% at day 5).
We further characterized these (total) neonatal eGFP+ cells by flow cytometric analysis to determine their 
surface marker expression. About 33.7% of these cells specifically expressed PDGF receptor alpha (Pdgfrα), 
~76.8% non-specifically expressed integrin beta-1 (Intgβ1), and ~22.0% expressed stem cell antigen-1 (Sca-1) 
(Fig. 2A,B). Moreover, these cells did not express CD45, a pan-hematopoietic marker; Thy1.1, a mesenchyme/ 
fibroblast marker; or hematopoietic stem/progenitor cell markers such as CD41 or c-Kit. Given that Pdgfrα has 
previously been described as a fibroblast or mesenchymal stem cell marker in the adult heart24,25, we compared 
the genome-wide transcriptional profile of eGFP+ cells isolated at embryonic days 13.5 (e13.5 GFP+ ) and 16.5 
(e16.5 GFP+ ) of development and from neonatal heart (neo P7 GFP+ ) with control neonatal CMs (neo CM) 
and cardiac fibroblasts from the adult heart (adult cardiac fib.) (Fig. 2C). Neonatal P7 eGFP+ cells expressed a 
distinct transcription profile from embryonic eGFP+ cells, neonatal CMs, or cardiac fibroblasts. To further probe 
the identity of these neonatal eGFP+ cells, we compared directly the genome-wide expression profile of embry-
onic day 10.5 (e10.5) CMs with P7 eGFP+ cells (Fig. 2D). The expression profile of P7 eGFP+ cells appeared 
quite distinct from that of e10.5 CMs. This was further supported by quantitative RT-PCR analysis showing that 
P7 eGFP+ cells express a number of cardiac transcription factors (e.g. MEF2C, GATA4, and GATA6) without 
a matching level of sarcomeric gene expression (e.g. troponin C1, T2, I3, cardiac actin, myl2, and myh6 and 7) 
(Fig. 2E,F).
Neonatal Nkx2.5 enh-eGFP+ cells possess the functional characteristics of neonatal cardio-
myoblasts. To address whether these neonatal Nkx2.5 enh-eGFP+ cells harbor a capacity for cardiovascular 
lineage differentiation, eGFP+ cells were isolated from 6-7 day-old hearts, FACS-purified, and subjected to either 
spontaneous differentiation or differentiation in coculture with embryonic CMs (eCMs), smooth muscle cells 
(SMCs), mouse embryonic fibroblasts (MEFs), or endothelial cells (ECs) (Fig. 3 and Supplementary Figure S2). 
eGFP+ cells cultured alone expressed little to no cardiac troponin T, whereas eGFP+ cells cocultured with eCMs 
for 8 days expressed both cardiac troponin T (~51% of cells, Supplementary Figure S2B,C, top row) and sarco-
meric actinin (~28% of cells) and adopted a striated CM phenotype (Fig. 3B–F). Single cell electrophysiolog-
ical assessment of an eCM-cocultured and subsequently disbursed eGFP+ cell revealed its ability to generate 
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Figure 1. Increase in neonatal heart-body weight. Wild-type C57/BL6 neonatal mice (n = 3/time point) 
were sacrificed at the indicated time point and their body (A) and heart (B) weights were measured. The 
ratio of heart weight to body weight remained relatively constant during the first 3 weeks after birth (C). (D) 
Schematic diagram of flow cytometric analysis of eGFP + cells from developing and neonatal (P4) Nkx2.5 
enh-eGFP hearts. (E) Quantification of the percentage of eGFP + cells in embryonic hearts and in the non-
myocyte fraction of neonatal hearts (n = 5/time point). (F) Quantitative PCR analysis of gene expression in 
FACS-purified GFP + (green) and GFP- (grey) cell populations (n = 5). Note that CM-associated cells localized 
predominantly in the eGFP- population. (G-H) Identification of proliferating Nkx2.5 enh-eGFP + cells in the 
neonatal heart. (G) Cell cycle analysis of eGFP + cells from day 6, 10, and 22 neonatal hearts (n = 3/time point). 
Shown is a representative flow cytometry plot of BrdU and 7-AAD incorporation into eGFP + cells. (H) The 
proportion of eGFP + cells in G0/1 (white), S (grey), and G2 (black) phases of cell cycle. The % of cells that are in 
G0/1 or S phases are indicated.
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Figure 2. Phenotypic characterization of neonatal Nkx2.5 enh-eGFP + cells. (A) Analysis of surface marker 
expression in eGFP + and eGFP- non-myocytes from the neonatal Nkx2.5 enh-eGFP heart. Shown are 
representative flow plots (n = 4). (B) Quantification of the percentage of eGFP + and eGFP- cells that express 
the indicated surface marker. (C) Genome-wide expression analysis of embryonic day 13.5 (n = 10), 16.5 
(n = 10), and neonatal P7 (n = 10) (total) GFP + cells against neonatal CMs (neo CM) (n = 10) and adult 
cardiac fibroblasts (n = 5). (D) Comparison of genome-wide transcriptional profile of neonatal eGFP + cells 
with embryonic day 10.5 (e10.5) CMs, isolated from wild type mice. (E,F) Quantitative PCR analysis of cardiac 
transcription factor (E) and sarcomeric gene (F) expression in neonatal day 7 (P7) eGFP + cells and e10.5 CMs.
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Figure 3. Functional characterization of neonatal Nkx2.5 enh-eGFP + cells. (A) Schematic illustration of 
in vitro differentiation of FACS-purified neonatal eGFP + cells into cardiomyocyte (CM), smooth muscle 
cell (SMC), and endothelial cell (EC), in coculture with embryonic day 10.5 CMs (eCMs), aortic SMCs, and 
endothelial cells, respectively (n = 5). (B–E) Immunofluorescent costaining for eGFP and α-sarcomeric 
actinin at 8 days after coculture followed by collagenase treatment and single cell re-plating. Scale = 20 µm. 
The inset in panel C shows a magnified view of sarcomeric structure in differentiated CM. (F) Quantification 
of the percentage of eCMs and cocultured eGFP + cells expressing α-sarcomeric actinin (n = 5). (G,H) 
Electrophysiological assessment of a control eCM and single re-plated eGFP + cell. The percentage of cells 
capable of spontaneous beating is shown (n = 33). (I–L) Immunofluorescent co-staining for eGFP and smooth 
muscle actin-α (SMA-α) at 8 days after coculture (n = 5). (M–P) Immunofluorescent co-staining for eGFP and 
CD31/PECAM at 8 days after coculture (n = 5). Scale bars = 20 µm.
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spontaneous action potentials (Fig. 3G,H). Interestingly, when neonatal eGFP+ cells were cocultured with aortic 
SMCs instead, a significant proportion of the cells expressed smooth muscle myosin heavy chain (SM-MHC) 
(Supplementary Figure SB-C, middle row) and smooth muscle actin-α (SMA-α) (Fig. 3I–L), and adopted smooth 
muscle cell morphology. This indicates that paracrine factors and/or cell-cell contact may play an important role 
in the conversion of eGFP cardiomyoblasts into functional CMs. On the other hand, coculturing of neonatal 
eGFP+ cells with endothelial cells minimally increased their expression of CD31 (Fig. 3M–P and Supplementary 
Figure S2B,C, bottom row), in support of their pre-existing commitment to myogenic lineages.
Differentiation of Nkx2.5 enh-eGFP+ cells into CMs in vivo. To address whether neonatal 
eGFP+ cells are able to expand and differentiate into mature CMs in vivo, we engineered a transgenic mouse 
line that expresses a Cre-eGFP fusion protein under the control of both Nkx2.5 cardiac enhancer and the reverse 
tetracycline transactivator (hereto referred as Nkx2.5 enh-Cre mouse) (Fig. 4A). By oral administration of dox-
ycycline, the Cre-eGFP fusion protein expression can be silenced, thus providing a temporal level of gene reg-
ulation. Similar to the Nkx2.5 enh-eGFP transgenic embryos at the same stages of development, the expression 
of eGFP in the Nkx2.5 enh-Cre transgenic embryos was restricted to the developing heart (Fig. 4B). When the 
Nkx2.5 enh-Cre mice were mated with the ROSA26FSLacZ reporter mice, the double transgenic embryos exhib-
ited cardiac-specific LacZ labeling (Fig. 4Ca–c). With gestational administration of doxycycline, the embryonic 
LacZ expression was completely abolished (Fig. 4Cd–f).
The ability to completely silence Nkx2.5 enh-Cre expression during embryonic development allowed us to 
determine whether the neonatal eGFP+ cardiomyoblasts were able to contribute to CM formation in the neo-
natal heart. To address this, we treated pregnant Nkx2.5 enh-Cre females that were mated with ROSA26FSLacZ 
males with doxycycline from conception until birth to suppress the embryonic expression of Cre-eGFP (Fig. 5A) 
and fully label Nkx2.5 enh-eGFP+ cells from P4 onwards when the doxycycline suppression of Cre expression is 
completely lost. We then assayed for the presence of LacZ+ cells at postnatal day 7 and 21 to determine whether 
neonatal Nkx2.5 enh-eGFP+ cardiomyoblasts had given rise to new CMs in the neonatal heart. We found that the 
Cre+ cardiomyoblasts and their descendant CMs were located in the subepicardial region in the neonatal heart 
at day 7 after birth (Fig. 5B). By day 21, many of these cells had migrated and differentiated into mature CMs and 
could be identified in the right and left ventricles (RV, LV) as well as in the interventricular septum IVS (Fig. 5C, 
c–h). Interestingly, sparse LacZ+ coronary SMCs were also be found within the vessel walls (Fig. 5C, g,h).
Embryonic origin of Nkx2.5 enh-eGFP+ cardiomyoblast. The subepicardial localization of new CMs 
from neonatal Nkx2.5 enh-eGFP+ cardiomyoblasts raises the possibility that the Nkx2.5 enh-eGFP+ cardio-
myoblasts might have originated from the developing epicardium. This would be consistent with recent studies 
showing the ability of developing and postnatal epicardial cells to differentiate into CMs26–28. We investigated 
whether subepicardial cardiomyoblasts in the neonatal heart originated from embryonic epicardial cells using 
a previously described inducible WT1-CreERT2 mice28 and found no evidence that these cells came from the 
developing epicardium (Supplementary Figure S3). This is consistent with results from a recent lineage tracing 
study of postnatal cardiac regeneration in the zebrafish heart6. We further examined whether neonatal cardio-
myoblasts descended from other precursor populations such as endothelial/endocardial (Tie2-Cre) or mature 
myocardial (alpha-myosin heavy chain-Cre) (αMHC-Cre) cell populations. No lineage relationship was found 
between developing endothelial/endocardial cells or mature CMs and the neonatal eGFP+ cardiomyoblasts. 
Instead, we show that neonatal eGFP+ cells are descendants from embryonic Nkx2.5 enh-eGFP+ cells in the 
fetal heart (Supplementary Figure S3).
Nkx2.5 enh-eGFP+ cardiomyoblast-mediated cardiomyogenesis in the neonatal heart 
is developmentally significant. To determine the consequences of the loss-of-function of Nkx2.5 
enh-eGFP+ cardiomyoblasts during neonatal heart formation, we treated compound heterozygous Nkx2.5 
enh-Cre;ROSA26FSDTA mouse embryos with doxycycline from conception until birth to suppress embryonic 
Cre expression (Fig. 6A). The ROSA26FSDTA mouse expresses diphtheria toxin upon Cre-mediated excision of 
the LoxP flanked stopper cassette29. The expression of Cre upon the cessation of doxycycline administration at 
birth results in excision of the stopper cassette in Cre+ cells, the production of DTA, and shortly after, the death of 
Nkx2.5 enh-Cre+ cells. As shown in Fig. 6B, mice with ablation of neonatal cardiomyoblasts (Cre+ /DTA+ mice 
– black bar) exhibited increased heart weight at 3, 6, and 9 weeks after birth compared with their littermate 
control (Cre-/DTA+ mice – white bar), without significant difference in their body weight (Fig. 6B). This sug-
gests that ablation of neonatal Nkx2.5+ cardiomyoblasts leads to early remodeling changes including ventricular 
hypertrophy. With further maturation (at 9 weeks), the ablated hearts exhibit mild ventricular enlargement as 
well (Fig. 6C). Ablation of Nkx2.5 enh-eGFP+ cell population did not compromise mice viability or health.
Discussion
The neonatal heart grows rapidly in both size and weight in order to meet the metabolic demands of the newborn. 
Beyond the first one or two weeks after birth, these increases in heart size and weight are thought to be mediated 
entirely by myocyte hypertrophy rather than proliferation30–32. In this study, we found a population of Nkx2.5 
enhancer+ cardiomyoblasts in the neonatal heart that can differentiate into striated CMs upon coculture with 
embryonic CMs. These cells are found initially in the subepicardial region and contribute progressively to new 
CMs in the right and left ventricles as well as the interventricular septum. Genetic ablation of these cells using a 
conditional diphtheria toxin A-expressing mice results in early heart failure phenotype. These data support the 
contribution of cardiomyoblasts to a defined proportion of the proliferating CMs in the neonatal heart and the 
requirement for CM proliferation to support normal neonatal heart development33,34.
www.nature.com/scientificreports/
7SCIeNTIfIC REPORtS | 7: 12590  | DOI:10.1038/s41598-017-12869-4
Figure 4. Generation and characterization of doxycycline-regulated Nkx2.5 enhancer-Cre transgenic mice. 
(A) Diagram of the plasmid construct used to generate the transgenic mice (top panel). Bottom panel: 
confirmation of the presence of transgenic sequence in founder mice by genomic PCR analysis. (B) Whole-
mount fluorescence microscopy of Nkx2.5 enh-Cre embryos at days 8.0 and 9.5 post coitum (n = 2). Note the 
cardiac-restricted expression of Cre-eGFP. (C) Analysis of Cre + cells and their lineage descendants in Nkx2.5 
enh-Cre /ROSA26FSLacZ transgenic embryos (n = 3) at 12.5 day post coitum in the absence (a,b,c) or presence 
(d,e,f) of doxycycline administration. (a,d) Whole mount bright field microscopy of X-Gal stained embryos. 
(b,c,e,f) Transverse sections of X-Gal stained embryos at day 12.5 post-coitum. Mid-Vent: Mid-ventricular. 
OFT: outflow tract.
www.nature.com/scientificreports/
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The reappearance of eGFP+ cells in the neonatal heart of Nkx2.5 enh-eGFP mice suggested a potential con-
tribution of cardiomyoblasts to the postnatal proliferative activity (Fig. 1G). qPCR analysis of isolated GFP+ and 
GFP- cells from the P6 neonatal mouse heart (Fig. 1F) demonstrated significantly lower Nkx2.5 expression level 
in the GFP+ cells, suggesting that the presence of the fetal enhancer activity in GFP+ cells does not precisely 
correlate with higher endogenous Nkx2.5 gene expression in postnatal cells. This can be explained by the fact that 
multiple enhancers are involved in controlling the activity of endogenous Nkx2.5 expression and other Nkx2.5 
Figure 5. Lineage labeling of neonatal cardiomyoblasts using doxycycline-regulated Nkx2.5 enhancer-Cre 
transgenic mice (A) Diagram of the experimental strategy to lineage label neonatal cardiomyoblasts and their 
progenies. (B,C) Detection of lineage descendants of neonatal Cre + cells in the hearts of Nkx2.5 enh-Cre/
ROSA26FSLacZ mice at day 7 (n = 3) (B) and 21 (n = 3) (C) after birth by X-gal staining.
www.nature.com/scientificreports/
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enhancers are more dominant in cardiac cells (e.g. cardiomyocytes) in the postnatal heart35. This can be due to 
the fact that different enhancers control the activity of Nkx2.5 expression and that in Nkx2.5 transcription itself is 
not specific to progenitors. The low expression levels of cardiac and endothelial genes in eGFP+ cells are line with 
our finding that these eGFP+ cells are mostly undifferentiated multipotent progenitors.
BrdU pulse-labeling of isolated Nkx2.5 enh-eGFP+ cells confirmed their residual proliferative activity that 
continued for a period (until P21) longer than previously described36,37. This data indicated that the proliferative 
capacity of eGFP+ cells was the greatest shortly after birth and declined over the first 3 weeks of life (Fig. 1J). The 
in vitro culture of P6 isolated eGFP+ cells confirmed their proliferative capacity (Ki67 and pH3 immunostain-
ing) which declined from day 1 to day 5, while the GFP- cells maintained their expression levels (Supplementary 
Figure S1). Phenotypic characterization of neonatal Nkx2.5 enh-eGFP+ cells, via both surface marker and 
genome-wide expression analysis, demonstrated remarkably distinct profile of these eGFP+ cells.
Our detailed characterization of the cellular phenotype of neonatal Nkx2.5 enhancer+ cardiomyoblasts 
revealed distinct properties of these cells from those described previously. Their expression of Pdgfrα (Fig. 2A,B) 
is consistent with their embryonic heart field origin given the previously reported labeling of embryonic38, post-
natal25, as well as embryonic stem cell-derived39 cardiac precursors with this marker. However, our genome-wide 
expression analysis revealed their distinct characteristic from either cardiac fibroblasts or embryonic CMs 
(Fig. 2C–F). It is worth noting that these eGFP+ cells exhibit a high level of expression of signaling molecules 
(e.g. Fgf8, Tgf-β2, Tgf-βR1, Gab1, Sema3C, Ednra) and transcription factors (e.g. Zfpm2, Nfatc4, Gli2, Pbrm1/
BAF180, Osr1) but not sarcomeric genes in comparison to that of fetal CMs (Fig. 2B,F). All together, the cell 
marker and genome-wide expression profiles of these neonatal Nkx2.5 enhancer+ cells are consistent with a cell 
population that is distinct from cardiac fibroblasts or mature CMs and suggests their role as a cardiomyoblast 
population.
Through a series of coculture experiments, we demonstrated the ability of neonatal Nkx2.5 enh-eGFP+ cells, 
cocultured with eCMs, to differentiate into striated CMs, expressing CM-specific troponin T and sarcomeric 
actinin (Fig. 3 and Supplementary Figure S2). In the ROSA-LacZ heart, it appeared that the expression of β-gal 
in each cell may be variable as a few ( <10%) of cells were weakly β-gal positive (Supplementary Figure S2). This 
Figure 6. Phenotype of neonatal mice following the deletion of Nkx2.5 + cardiomyoblasts. (A) Breeding 
and doxycycline treatment strategy for Cre/LoxP-mediated ablation of neonatal Nkx2.5 + cardiomyoblasts. 
The excision of the stopper cassette results in diphtheria toxin A (DTA) expression in Cre-expressing 
cells. (B) The hypertrophic response of neonatal mouse hearts that have undergone ablation of their 
Nkx2.5 + cardiomyoblasts shortly after birth. The body weight (left panel), heart weight (middle panel), and 
the ratio of heart weight to body weight (right panel) are shown (n = 4 for each time point). (C) Histological 
examination of hearts in mice with deficiency of Nkx2.5 + cardiomyoblasts. At 9 weeks old, the cardiomyoblast-
deficient hearts (Cre + /DTA + ) are larger in size than that of their littermate control (Cre-/DTA+ ) (right 
panel).
www.nature.com/scientificreports/
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could be due to the fact that the β-gal expression from the ROSA26 locus is not uniformly strong in all cells 
in postnatal tissue. This differentiation of eGFP+ cells into CMs depends on paracrine and/or contact factors 
since little to no cardiac troponin T+ cells was generated from spontaneous differentiation of eGFP+ cells. The 
cardiomyogenic phenotype of eCM-cocultured eGFP+ cells was not due to cell-cell fusion since the majority of 
sarcomeric actinin/eGFP double positive cells exhibited only one single nucleus (Fig. 2B–D). Consistent with our 
previous reports20, the Nkx2.5 enh-eGFP+ cells demonstrated a remarkable capacity to differentiate into SMCs 
both in vitro (Fig. 3 and Supplementary Figure S2) and in vivo (Fig. 5). These findings provide strong support that 
neonatal Nkx2.5 enh-eGFP+ cells represent a population of cardiomyoblasts in the neonatal heart. For future 
studies, it would be of high interest to unravel the molecular pathways driving these cell-fate decisions to either 
become myocardium, smooth muscle or endothelium.
The capacity of Nkx2.5 + cardiomyoblasts in the neonatal heart to expand, differentiate, and mature into CMs 
in vivo raises an interesting question regarding their importance during neonatal cardiac development. Using the 
newly engineered Nkx2.5 enh-Cre mouse model, we found that Nkx2.5 + cardiomyoblasts gave rise to new CMs 
in the subepicardium that progressively migrated inward to contribute to new CMs in the right and left ventricles 
and interventricular septum (Fig. 5). This is while a small fraction of LacZ + cardiomyoblasts differentiated to 
SMCs, residing within the vessel walls (CM to SMC percentage ratio of ~87:13) (Fig. 5C,g,h). FACS analysis of 
the P0 isolated eGFP+ cells which were co-stained with cardiac Troponin T (cTnT) demonstrated a negligible 
fraction eGFP + cells expressing cTnT (~0.01% of total cells) (Supplementary Figure S4).
In support of the importance of these cells to normal cardiac development, we found that the ablation of these 
cells led to enlarged heart size, elevated heart/body weight ratio, and left ventricular hypertrophy that eventually 
dilate over time (Fig. 6C). This pattern is consistent with the progression of many pediatric cardiomyopathies and 
suggests that modulation of cardiomyoblast proliferation and differentiation may be therapeutically relevant in 
this patient population40. Further analyses (e.g., echocardiography or immunohistochemistry of cardiac disease 
markers) would be required to achieve a greater understanding of the role of Nkx2.5 enh-eGFP+ cardiomyoblasts 
in maintaining the function of developing heart. Moreover, we are currently investigating the potential role of 
Nkx2.5-enh-eGFP+ cells on the heart regenerative response in a myocardial infarction model in postnatal regen-
erative window (P0-P7), juvenile (P21), and adult (7–12 weeks old) mice. Taken together, these results support 
the requirement of neonatal Nkx2.5 enh-eGFP+ cardiomyoblasts to generate functional CMs during normal 
cardiac development.
Methods
Mice. Newborn wild type C57/BL6 mice (Jackson Laboratory, Barharbor, ME) were sacrificed at days 1–21 
and their body and heart weights were measured. Euthanasia was performed by first sedating the mice via iso-
flurane (inhalant, 2% in 100% oxygen, neonate placed on a warm pad), followed by a secondary cervical dislo-
cation41. Death was verified after euthanasia and prior to disposal. Nkx2.5 cardiac enhancer-eGFP transgenic 
mice (Nkx2.5 enh-eGFP) were previously described20. Doxycycline-regulated Nkx2.5 enhancer-Cre-eGFP trans-
genic mice (Nkx2.5 enh-Cre) were made by pronuclear injection of one-cell C57BL/5 mouse embryos and trans-
ferred to CD1 pseudopregnant foster females. From four original transgene-carrying founders, the line with 
the most robust expression of Cre-eGFP in the developing heart was further studied. ROSA26-flox-stop-flox-
LacZ reporter mice (ROSA26FSLacZ) were obtained commercially from Jackson Laboratory (Bar harbor, ME). 
CM-specific alpha-myosin heavy chain-Cre (α-MHC-Cre), endothelial Tie2-Cre, and ROSA26-flox-eGFP-flox-
diptheria toxin A (ROSA26FSDTA) mice were described previously29,42,43. All animal experiments were approved 
by the Subcommittee on Research Animal Care at Massachusetts General Hospital and by the animal care and 
use committee (APLAC) at Stanford University. All experiments were performed in accordance with relevant 
guidelines and regulations of Massachusetts General Hospital.
Body and heart weight measurements. To determine the heart weight and body weight of neonatal 
mice, we sacrificed mice at the indicated age (by day) of development. Their overall body weight was measured 
and the hearts were dissected and cleared with deionized water and measured from day 1 to 21 after birth. In 
experiments involving transgenic mice that have undergone Cre-mediated ablation of neonatal Nkx2.5 + cardi-
omyoblasts, the body and heart weights were measured at 0.5, 3, 6, and 9 weeks after birth and compared with 
those of the littermate control without Cre transgene.
Histology, immunohistochemistry, and immunofluorescence. Freshly isolated adult and embry-
onic mouse hearts were dissected from mouse chest cavity and washed in PBS to remove excess blood. For Nkx2.5 
enh-eGFP and Nkx2.5 enh-Cre embryos at days 8.0 and 9.5 post coitum, their heart tube was dissected away 
from the body and imaged immediately with whole mount fluorescence microscopy. For late fetal and postnatal 
hearts, they were incubated in 30% sucrose in PBS overnight followed by step-wise incubation with a graded 
concentration of OCT in PBS for cryosectioning. Following cryopreservation, hearts were cut into 10 μm sections 
and lightly fixed in 4% paraformaldehyde in PBS prior to immunostaining. For detection of CM differentiation, 
antibodies against α-sarcomeric-actinin (1:200; Sigma-Aldrich, St. Louis, MO) and cardiac troponin-T (1:200; 
polyclonal, Chemicon) were used. For visualization, fluorescence detection with Alexa Fluor® secondary anti-
bodies (Invitrogen, Carlsbad, CA) towards the appropriate primary antibodies was used. For β-galactosidase 
staining, freshly dissected mouse hearts were prepared as described above and incubated at 37 °C in 1 mg/ml 
X-Gal substrate (Fisher Scientific). The X-Gal stained sections were then counterstained with Nuclear Fast Red 
and/or co-stained with antibodies for co-immunofluorescent studies. Hematoxylin and eosin staining of histo-
logical sections was performed according to manufacturer suggested protocol. All quantitative analyses of the 
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histological sections were performed on numerically-coded animals in an observer-blinded fashion to prevent 
subjective bias in data analysis.
Cell isolation, flow cytometry, FACS sorting, and cell cycle analysis. At indicated age, freshly iso-
lated hearts from embryonic and neonatal Nkx2.5 enh-eGFP transgenic mice were immediately minced and 
digested with collagenase (collagenase A 10 mg/ml and B 10 mg/ml, Roche, Sigma-Aldrich) in 10 mM HEPES 
buffered solution with 20% FBS at 37 °C for 60 min. Single-cell suspension was obtained by trituration every 
15 min during incubation followed by removal of undigested tissue with a 40 μm cell strainer. eGFP+ live cells, as 
defined by propidium iodine negativity, were analyzed by flow cytometry using FACSCalibur® (BD Biosciences) 
or isolated using FACSAria® (BD Biosciences) and cultured in differentiation medium (DM) containing IMDM 
(Invitrogen), 20% FCS (Invitrogen), 5000 i.u./ml penicillin/streptomycin (Invitrogen), 200 mM L-glutamine 
(Invitrogen), 1.5 × 10−4M 1-thioglycerol (Sigma-Aldrich), and 50 μg/ml ascorbic acid (Sigma-Aldrich). For 
co-culture experiments, Nkx2.5 enh-eGFP+ sorted cells were first transfected with a GFP expressing lentivirus to 
permanently label these cells before their differentiation begins.
For cell cycle analysis, BrdU was injected into the peritoneum of neonatal (only once, at day 5 or 20) Nkx2.5 
enh-eGFP+ and wild-type mice. At 5 hrs after injection (wild type) or 24 hrs after injection (Nkx2.5 enh-eGFP+ ) 
the hearts were harvested for collagenase treatment and flow cytometry analysis using a combination of 
7-AAD and anti-BrdU-APC antibody (BD Biosciences). Flow cytometry and cell cycle data were acquired on a 
FACSCalibur® (BD Biosciences) flow cytometer and processed by FlowJo software (Treestar). The flow cytometry 
antibodies used were APC-conjugated anti-mouse CD4, CD8, CD45, Gr-1, Mac-1, B220, and c-Kit (from eBio-
science) as well as PDGF receptor alpha (Pdgfrα), integrin beta-1 (Intgβ1), stem cell antigen-1 (Sca-1), CD45, 
Thy1.1, and CD41 (from BD Biosciences).
Preparation of neonatal CMs and adult cardiac fibroblasts. Hearts were extracted from neonatal 
mice (P7) and immediately transferred into the dish containing 1× PBS on ice and washed twice. Subsequently, 
heart were transferred into the isolation medium (20 mM BDM, 0.0125% trypsin, in HBSS) and minced into 
small pieces (on ice). Minced hearts were transferred into a tube containing isolation medium and incubated 
with gentle agitation at 4 °C overnight. Predigested hearts containing tissue fragments were further digested using 
collagenase (15 mg in 10 mL of L15 medium) at 37 °C for 20 minutes. Neonatal CMs were then strained (40 μm), 
centrifuged (300 rpm- 5 min), resuspended, and plated onto collagen-coated cell culture plates (Sigma C-8919) 
using plating medium (65% DMEM, 19% M-199, 15% fetal calf serum, 1% penicillin/streptomycin)44. To prepare 
cardiac fibroblasts, adult mouse hearts were extracted, washed twice with ice cold PBS, and minced on ice (~1 
mm). Minced tissue was digested using collagenase (1% v/v collagenase II in HBSS buffer) under constant stirring 
at 37 °C for 20–30 min. Once fully digested, the supernatant was transferred to a tube (on ice) containing 1 ml 
fibroblast medium (DMEM/F12 with 10% FBS, 100 U/ml Pen/Strep, 1× L-glutamine, and 100 µM ascorbic acid), 
centrifuged (300 g, 5 min), and resuspend in fibroblast medium. Cardiac fibroblasts were plated into 10-cm cell 
culture dishes and incubated at 37 °C in a cell culture incubator with 5% CO2 for 2 hrs. Once fibroblasts adhered 
onto the dish, we discarded the supernatant, rinsed the cells with PBS (3x) and added fresh fibroblast medium45.
Microarray analysis. The oligonucleotide microarrays were performed by WELGENE Microarray Service 
(Taiwan). 0.2 μg of total RNA was amplified by a Low Input Quick-Amp Labeling kit (Agilent Technologies, USA) 
and labeled with Cy3 (CyDye, Agilent Technologies, USA) during the in vitro transcription process. 0.6 μg of 
Cy3-labled cRNA was fragmented to an average size of about 50–100 nucleotides by incubation with fragmenta-
tion buffer at 60 °C for 30 minutes. Correspondingly fragmented labeled cRNA was then pooled and hybridized 
to Agilent SurePrint G3 Mouse GE 8 × 60 K Microarray (Agilent Technologies, USA) at 65 °C for 17 h. After 
washing and drying by nitrogen gun blowing, microarrays were scanned with an Agilent microarray scanner 
(Agilent Technologies, USA) at 535 nm for Cy3. Scanned images were analyzed by Feature extraction10.5.1.1 
software (Agilent Technologies, USA), an image analysis and normalization software used to quantify signal and 
background intensity for each feature.
Electrophysiological studies of differentiated eGFP+ cardiomyoblasts. FACS-purified Nkx2.5 
enh-eGFP+ cells, isolated from 7–10 day-old neonatal hearts were either cultured alone or cocultured with: 
embryonic day 10 CMs (eCMs, in differentiation medium), smooth muscle cells (SMCs), mouse embryonic 
fibroblasts (MEFs), or endothelial cells (ECs), for 8 days. For all in vitro studies, we used 0.1% gelatin for coating 
culture substrates. Prior to electrophysiological studies, cocultured eGFP+ cells were dispersed into single cells 
by collagenase treatment and replated onto 1 cm-diameter round coverslips. Cells on coverslips were bathed in 
extracellular solution containing 140 mM NaCl, 2.8 mM KCl, 2 mM CaCl2, 2 mM MgCl2, 10 mM HEPES, and 
10 mM glucose, at pH 7.4. Patch electrodes were filled with an intracellular solution containing 140 mM potas-
sium gluconate, 10 mM NaCl, 2 mM MgCl2, 10 mM HEPES, 1 mM EGTA, 4 mM Mg-ATP, and 0.3 mM Na-GTP, 
at pH 7.3, hence, giving resistances of ~2–5 MΏ. Spontaneous CM action potentials were recorded at room tem-
perature in current clamp mode as previously described [20].
PCR and quantitative PCR analysis of gene expression. To determine the Cre excision status of LoxP 
flanked stopper sequence in the ROSA26FSLacZ allele of Nkx2.5 enh-eGFP+ cells, eGFP+ cells from the digested 
hearts of α-MHC–Cre, doxycycline-regulated Nkx2.5 enh-Cre, WT1-CreERT2, and Tie2-Cre transgenic mice 
were purified by FACS and cultured briefly before their cellular genomic DNA was isolated using the Gentra 
Puregene kit (Qiagen). These purified DNA samples were PCR amplified with ROSA26 locus-specific primers 
for the presence of Cre-mediated excision (i.e. 1Lox). The primer sequences are TGG CTT ATC CAA CCC CTA 
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GA (forward), and GTT TTC CCA GTC ACG ACG TT (reverse). Amplification of the HPRT locus was used as 
an internal PCR control.
For quantitative analysis of gene expression, FACS-purified eGFP+ cells from freshly isolated and collagenase 
digested hearts were lysed with Trizol (Invitrogen) and stored at −80 °C. Total RNA from each sample was puri-
fied from cell lysate using the SV Total RNA kit (Promega). cDNA was made using iScript cDNA synthesis kit 
(BioRad). Quantitative PCR was performed using the Mastercycler EP Realplex system (Eppendorf) with SYBR 
Green substrate (BioRad) for 40 cycles.
Data analysis. Numerical data are presented as mean ± SEM. Statistical significance was performed using a 
two-tailed paired t-test with equal variance. Correlation between groups was assessed with Pearson correlation 
coefficients (R). Values of p < 0.05 were considered statistically significant.
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